Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 1/20 | 0.45 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.38 |
| ▸ | HTR2A | P28223 | 2/20 | 0.36 |
| ▸ | HTR2C | P28335 | 2/20 | 0.36 |
| ▸ | KDM1A | O60341 | 3/20 | 0.34 |
| ▸ | KDM1B | Q8NB78 | 1/20 | 0.34 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.34 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.34 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.33 |
| ▸ | HTR1A | P08908 | 1/20 | 0.33 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.33 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.33 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.33 |
| ▸ | TYMS | P04818 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6386269 | 0.82 | HTR2A (0.50) | CYP2D6HTR2A | |
| SCHEMBL6385703 | 0.77 | CYP2D6 (0.40) | CYP2D6MAPK14HTR2AHTR2CCYP11B2 | |
| SCHEMBL4238327 | 0.74 | TYMS (0.37) | CYP2D6KDM1AKDM1BCYP11B2HTR1A | |
| SCHEMBL5941266 | 0.70 | ANPEP (0.42) | CYP2D6MAPK14TRPM8 | |
| SCHEMBL10415991 | 0.67 | CYP2D6 (0.46) | CYP2D6HTR2A | |
| SCHEMBL6387798 | 0.67 | MAPK14 (0.43) | CYP2D6MAPK14CYP11B2TYMS | |
| SCHEMBL6387801 | 0.67 | MAPK14 (0.43) | CYP2D6MAPK14CYP11B2TYMS | |
| SCHEMBL6387885 | 0.67 | MAPK14 (0.60) | MAPK14TYMS | |
| Hydrochloric Acid SCHEMBL10416486 | 0.66 | CYP2D6 (0.45) | CYP2D6HTR2ACYP11B2 | |
| SCHEMBL10415988 | 0.66 | CYP2D6 (0.64) | CYP2D6HTR1ASLC6A2SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090099195-A1 | Therapeutic Compounds 570 | ASTRAZENECA AB (SE) | 2009-04-16 | — | — | US | disclosed |
| US-20050245503-A1 | Therapeutic heterocycles | ASTRAZENECA AB (SE) | 2005-11-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090099195-A1 | Therapeutic Compounds 570 | OPRL1, OPRK1, OPRM1 | CYP2D6 50/4885MAPK14 3850/4885HTR2A 1464/4885 |
| US-20050245503-A1 | Therapeutic heterocycles | OPRK1, RECQL, OPRM1 | CYP2D6 61/4885MAPK14 4334/4885HTR2A 282/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.